YKL-40 was suggested to be an independent biomarker for the inflammatory/atherosclerotic processes in T2D patients (Rathcke and Vestergaard, 2006; Rathcke et al. 2006). This evidence concerns the gene CHI3L1 and type 2 diabetes mellitus.